Consistency of quantitation of HCV genotype 4 from egypt across three HCV-RNA amplification assays
Fathia Zaky El Sharkawi
Faculty of Pharmacy, Biochemistry Department, Helwan University, Ein Helwan, Cairo, Egypt
Search for more papers by this authorCorresponding Author
C. Micha Nübling
Paul-Ehrlich-Institut, Langen, Germany
Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany.===Search for more papers by this authorFathia Zaky El Sharkawi
Faculty of Pharmacy, Biochemistry Department, Helwan University, Ein Helwan, Cairo, Egypt
Search for more papers by this authorCorresponding Author
C. Micha Nübling
Paul-Ehrlich-Institut, Langen, Germany
Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany.===Search for more papers by this authorAbstract
Different quantitative assays for HCV-RNA are available that report test results in International Units (IU)/ml based on the WHO International Standard. Thus, assays have been calibrated with standard material containing HCV genotype 1, so the consistency of quantitation might differ between assays for other HCV genotypes. Three commercial HCV nucleic acid amplification techniques (HCV–NAT) were compared for quantitation consistency of genotype 4 and 1 specimens from an Egyptian blood donor panel (n = 92). Consistency of quantitation between HCV–NATs was higher for genotype 1 than for genotype 4. Most quantitative results reported by the assays were in the same range, but some genotype 4 samples were missed by two of the assays. The Abbott assay showed higher concentrations for genotype 4 than the two Roche assays. Follow-up investigations of individuals should use the same assay unless another assay has been validated properly. Standardization of HCV–NAT assays remains an issue. J. Med. Virol. 80:2086–2091, 2008. © 2008 Wiley-Liss, Inc.
REFERENCES
- Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. 1989. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321: 1494–1500.
- Candotti D, Temple J, Sarkodie F, Allain JP. 2003. Frequent recovery and broad genotype 2 diversity characterize hepatitis C virus infection in Ghana, West Africa. J Virol 77: 7914–7923.
- Dhillon AP, Dusheiko GM. 1995. Pathology of hepatitis C virus infection. Histopathology 26: 297–309.
- EL-Sahly AM, Nour EL Din MA, Abdel-Rahman HM. 1991. Prevalence of antibodies to HCV in Egyptian patients with Schistosomiasis. The National Congress of the Egyptian Society of Hepatology.
- EL-Sharkawi F. 2000. Genotyping of Hepatitis C Virus in Egypt. PhD Thesis, Faculty of Pharmacy, Cairo University, Egypt.
- European Commission. 1998. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Off J Eur Commun. L 331/1.
- European Commission. 2002. Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices. Off J Eur Commun. L 131/17.
- Fretz CD, Jeannel L, Stuyvr V, Herve F, Lunel A, Boudifa C, Mathiot G, de THE, Fournel JJ. 1995. HCV infection in a rural population of Central African Republic (CAR). Epidemiology and evidence for two new subtypes of genotype 4. J Med Virol 47: 435–437.
- Halim AB, Garry RF, Dash S, Gerber MA. 1999. Effect of Schistosomiasis and hepatitis on liver disease. Am J Trop Med Hyg 60: 915–920.
-
Jeannel D,
Fretz C,
Traore Y,
Kohdjo N,
Bigot A,
Gamy EP,
Jourdan G,
Kourouma K,
Martens G,
Fuloux F,
Fournel JJ,
Stuyver L.
1998.
Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa.
J Med Virol
55:
92–97.
10.1002/(SICI)1096-9071(199806)55:2<92::AID-JMV2>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH. 1990. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma. Hepatology 12: 671–675.
- Kretzschmar E, Chudy M, Nübling CM, Ross RS, Kruse F, Trobisch H. 2007. First case of hepatitis C virus transmission by a red blood cell concentrate after introduction of nucleic acid amplification technique screening in Germany: A comparative study with various assays. Vox Sang 92: 297–301.
- Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC. 1993. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 341: 1501–1504.
- Lin LIK. 1989. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45: 255–268.
- Lin LIK. 1992. Assay validation using the concordance correlation coefficient. Biometrics 48: 599–604.
- Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V. 1995. Pretreatment serum hepatitis C virus genotype are the main and independent prognosis factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 22: 1050–1056.
- Mellor J, Holmes EC, Jarvis LM, Yap PL, Simmonds P. 1995. Investigation of the pattern of hepatitis C sequence diversity in different geographical regions: implantations for virus classification. J Gen Virol 76: 2493–2507.
- National Institutes of Health (NIH). 1997. NIH consensus statement. Management of hepatitis C, Bethesda, MD, March 24-26, I5: 1–41.
- Ndjomou J, Pybus OG, Matz B. 2003. Phylogenic analysis of hepatitis C virus isolates indicates a unique pattern of endemic infection in Cameroon. J Gen Virol 84: 2333–2341.
- Pawlotsky JM. 2002. Molecular diagnosis of viral hepatitis. Gastroenterology 22: 1554–1568.
- Pawlotsky JM, Tsakiris L, Roudot- Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeax D. 1995. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 171: 1607–1610.
- Pfleiderer C, Blümel J, Schmidt M, Roth WK, Hourfar MK, Eckert J, Chudy M, Menichetti E, Lechner S, Nübling CM. 2008. West Nile Virus and blood product safety in Germany. J Med Virol 80: 557–563.
- Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. 2000. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 182: 698–707.
- Ruggieri A, Argentini C, Kourouma K, Chionne P, Ugo ED, Spada E, Dettori S, Sabbatici S, Rapicetta M. 1996. Heterogencity of hepatitis C virus genotype 2 variants in West Central Africa (Guinea Conakry). J Gen Virol 77: 2073–2076.
- Saldanha J, Lelie N, Heath A. 1999. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang 76: 149–158.
- Shiratori Y, Kato N, Yokosuka O, Imazeki F, Hashimoto E, Hayashi N, Nakamura A, Asada M, Kuroda H, Tanaka N, Arakawa Y, Omata M. 1997. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 13: 558–566.
- Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, Holmes EC. 1994. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol 75: 1053–1061.
- Simmonds P. 2004. Genetic diversity and evolution of hepatitis C virus -15 years on. J Gen Virol 85: 3173–3188.
- Smith DB, Mellor J, Jarvis LM, Davidson F, Kolberg J, Urdea M, Yap PL, Simmonds P. 1995. Variation of the hepatitis C virus 5' non-coding region: implications for secondary structure, virus detection and typing. The International HCV Collaborative Study Group. J Gen Virol 76: 1749–1761.
- Zaaijer HL, Cuypers HT, Reesink HW, Winkel IN, Gerken G, Lelie PN. 1993. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 341: 722–724.
- Zeller HG, Schuffenecker I. 2004. West Nile virus. An overview of its spread in Europe and in the Mediterranean Basin in contrast to its spread in the Americas. Eur J Clin Microbiol Infect Dis 23: 147–156.